- Home
- PEPG vs SLN Comparison
PEPG vs SLN Comparison
Compare PEPG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- SLN
- Stock Information
- Founded
- PEPG 2018
- SLN 1994
- Country
- PEPG United States
- SLN United Kingdom
- Employees
- PEPG N/A
- SLN N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- SLN Health Care
- Exchange
- PEPG Nasdaq
- SLN Nasdaq
- Market Cap
- PEPG 317.6M
- SLN 345.3M
- IPO Year
- PEPG 2022
- SLN N/A
- Fundamental
- Price
- PEPG $4.51
- SLN $7.23
- Analyst Decision
- PEPG Strong Buy
- SLN Buy
- Analyst Count
- PEPG 6
- SLN 6
- Target Price
- PEPG $9.17
- SLN $39.67
- AVG Volume (30 Days)
- PEPG 970.7K
- SLN 183.2K
- Earning Date
- PEPG 11-06-2025
- SLN 11-13-2025
- Dividend Yield
- PEPG N/A
- SLN N/A
- EPS Growth
- PEPG N/A
- SLN N/A
- EPS
- PEPG N/A
- SLN N/A
- Revenue
- PEPG N/A
- SLN $27,169,000.00
- Revenue This Year
- PEPG N/A
- SLN N/A
- Revenue Next Year
- PEPG N/A
- SLN N/A
- P/E Ratio
- PEPG N/A
- SLN N/A
- Revenue Growth
- PEPG N/A
- SLN 22.28
- 52 Week Low
- PEPG $0.88
- SLN $1.97
- 52 Week High
- PEPG $7.62
- SLN $18.29
- Technical
- Relative Strength Index (RSI)
- PEPG 52.66
- SLN 66.41
- Support Level
- PEPG $4.36
- SLN $6.92
- Resistance Level
- PEPG $5.65
- SLN $7.75
- Average True Range (ATR)
- PEPG 0.40
- SLN 0.55
- MACD
- PEPG -0.12
- SLN 0.10
- Stochastic Oscillator
- PEPG 11.64
- SLN 80.29
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.